drugset / Trial / NCT01751893

Testing the Effectiveness of Henna on Managing PPE

NCT01751893 ↗

Completed 56 enrolled Cyprus University of Technology
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The palmar-plantar erythrodysesthesia (PPE) is the only clinical adverse event that commonly occurs with capecitabine and/or pegylated liposomal doxorubicin treatment and it warrants special attention because it is the most common dose-limiting toxicity. this study is designed to test the effectiveness of a henna treatment protocol in the management of capecitabine and/or pegylated liposomal doxorubicin induced palmar-plantar erythrodysesthesia.

Timeline

Start
2017-06-01
Primary completion
2018-05-01
Completion
2018-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Henna Unknown 40 g Topical

Indications